louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01431001: Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Official title: Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depressive Disorder
Keywords: Depression
MDD
Transcranial Magnetic Stimulation
Depressive Disorder
TMS
Lead sponsor: Cervel Neurotech, Inc.
Sponsor class: INDUSTRY
First posted: 2011-09-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of a Deep Shaped-Field repetitive transcranial magnetic stimulation (DSF-rTMS) system in the treatment of depression.


Eligibility criteria: Inclusion Criteria:

* Major depressive disorder (MDD)
* Mild to moderate level of resistance or intolerance to antidepressant treatment in the current episode.
* Will not become pregnant during study.

Exclusion Criteria:

* Seizure disorder.
* History of brain injury or active CNS disease.
* Metal implants on or in brain, spinal cord, ear, eye or heart.
* Current use of proconvulsant medications (e.g., bupropion).
* Other significant psychiatric disorder.
* Substance use disorder (not including caffeine or nicotine).
* 7 or more failed treatment attempts for depression in one's lifetime.
* Have failed to clinically remit to an adequate trial of ECT or TMS.

Primary outcomes:
measure: Remission from depression
timeFrame: baseline through 4 weeks post
Secondary outcomes:
measure: Safety and tolerability of rTMS
timeFrame: baseline through 4 weeks post
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Chicago
country: United States
facility: Rush Medical College
state: Illinois
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Melbourne
country: Australia
facility: Monash Alfred Psychiatry Research Centre
state: Victoria
Study officials:
affiliation: Cervel Neurotech
name: AnnaMarie Daniels
role: STUDY_CHAIR
References:
Clinical trial NCT04551001: Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy
Official title: Randomized Controlled Trial Investigating Cold Snare aNd Forcep polypectomY Among Small POLYPs in Rates of Complete Resection: the TINYPOLYP Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colo-rectal Cancer
Polyp of Colon
Adenomatous Polyp of Colon
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2020-09-16
Enrollment: 181
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The focus of the study is to evaluate impact of cold forcep and cold snare in achieving complete resection during polypectomy of polyps \<=3mm during colonoscopy.

Detailed description: The details of the proposed study are as follows:

1. Experimental group: using cold forceps for polyps \<=3mm of the colon
2. Control group: using cold snare for polyps \<=3mm of the colon
3. Methods:

   1. Colonoscopy will be performed in the same standard of care manner as if no study was taking place.
   2. If polyps \<=3mm are identified, the endoscopist is randomized to performing polypectomy with cold forcep or cold snare.
   3. After removal of the polypectomy, two biopsies are performed at the margin of the polypectomy site to identify residual lesion.
   4. The polyp as well as well as the two biopsies are reviewed by a pathologist.

Eligibility criteria: Inclusion Criteria:

* Patients 18 years or older
* Polyps \<=3mm

Exclusion Criteria:

* Pregnant
* Inflammatory bowel disease
* Polyposis syndromes

Primary outcomes:
measure: Completeness of resection
timeFrame: 2 weeks
Secondary outcomes:
measure: Time to resection
timeFrame: During the procedure
measure: Number of forcep bites or snare attempts
timeFrame: During the procedure
measure: Complications
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Veterans Affairs Palo Alto Health Care System
state: California
Study officials:
affiliation: Stanford University
name: Shai Friedland, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wei MT, Louie CY, Chen Y, Pan JY, Quan SY, Wong R, Brown R, Clark M, Jensen K, Lau H, Friedland S. Randomized Controlled Trial Investigating Cold Snare and Forceps Polypectomy Among Small POLYPs in Rates of Complete Resection: The TINYPOLYP Trial. Am J Gastroenterol. 2022 Aug 1;117(8):1305-1310. doi: 10.14309/ajg.0000000000001799. Epub 2022 Apr 25.
Clinical trial NCT06413901: TIP Repair of Distal Penile Hypospadias Using Rapidly Absorbable Braided Vs Slowly Absorbable Monofilament Sutures
Official title: TIP Repair of Distal Penile Hypospadias Using Rapidly Absorbable Braided Vs Slowly Absorbable Monofilament Sutures: A Prospective, Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypospadias Repair
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-05-14
Enrollment: 69
Sex: MALE
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective:

To study the effect of tubularizing the urethral plate in DPH in children using 2 different absorbable suture materials, rapidly absorbable, braided 6/0 Vicryl and slowly absorbable monofilament 6/0 Polydioxanone, on complication rates.

Patients and methods:

A prospective, randomized controlled study conducted at the Urology Department, Cairo University Specialized Pediatric Hospital, Abou El Reesh, between September 2021 and September 2022. A total of 69 boys aged between 8 and 120 months with DPH were randomly divided into 2 groups: group(A) Vicryl included 39 boys and group(B) PDS included 30 boys. All boys were uncircumcised with no chordee and were primary repairs. TIP was the surgical technique used by a single pediatric urologist. Follow up was performed in outpatient clinic at 7 days, 1, 3, 6 and 12 months postoperatively. The complications and reoperation rates for both groups were compared.


Eligibility criteria: Inclusion Criteria:

* Any child(aged from 6m to 12 years old) with distal penile hypospadias (DPH) ( uncircumcised, without chordae, with good penile size and urethral plate(candidates for T.I.P repair)

Exclusion Criteria:

* reccurent cases,
* circumcised cases
* other types of hypospadias rather than DPH,
* presence of chordae,
* poor urethral plate

Primary outcomes:
measure: complication rate
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT01072201: To Access the Effects of Mucositis in Adults With Dental Implants
Official title: To Access the Effects of Mucositis in Adults With Dental Implants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Mucositis
Lead sponsor: Colgate Palmolive
Sponsor class: INDUSTRY
First posted: 2010-02-19
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical research for the treatment of mucositis subjects who have dental implants for a minimum of one-year.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects, ages 30-70.
* Availability for the six-month duration of the clinical research study.
* Good general health.
* Subjects who have lost teeth for periodontal disease reasons and who have been restored with implants.
* Minimum of 5 remaining teeth and a minimum of 2 implants.
* Initial evaluation of the gingival and peri-implant mucosal tissues by determining full mouth bleeding on probing.
* Initial plaque evaluation by determining full mouth presence/absence of plaque.
* Signed Informed Consent Form.

Exclusion Criteria:

* Tumor(s) of the soft or hard tissues of the oral cavity.
* Untreated periodontal disease (purulent exudate, tooth mobility, and/or extensive loss or periodontal attachment or alveolar bone).
* Carious lesions requiring immediate restorative treatment.
* Uncontrolled Diabetes
* Use of antibiotics any time during the one month prior to entry into the study.
* Untreated peri-implantitis.
* Participation in any other clinical research study or test panel within the three months prior to entry into the study.
* Pregnant women or women who are breast feeding.
* History of allergies to personal care/consumer products or their ingredients.
* Medical condition which prohibits not eating/drinking for up to 2 hours.
* Current alcohol or drug abuse.
* Systemic or local disease conditions that would compromise post-operative healing.
* Regular use of anti-inflammatory drugs.

Primary outcomes:
measure: Bleeding on Probing
timeFrame: 6 months
measure: Mean Pocket Depth
timeFrame: 6 Months
measure: Mean Percentage of Plaque Scores
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Rimini
country: Italy
facility: Ariminum Research & Dental Education Center
Study officials:
name: Per Ramberg, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00075101: Sleep, Fatigue, and Dexamethosone in Children With Leukemia
Official title: Sleep, Fatigue, and Dexamethosone in Childhood Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Leukemia
Keywords: Drug Adverse Effect
Pediatric Cancer
Lead sponsor: National Institute of Nursing Research (NINR)
Sponsor class: NIH
First posted: 2004-01-05
Enrollment: 134
Sex: ALL
Minimum age (years): 5
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the relationship between dexamethosone (steroid) and children's sleep and fatigue.

Detailed description: Approximately 134 children and adolescents will be enrolled. All children and adolescents will wear a wrist actigraph for two consecutive 5-day study periods. Children and adolescents will have blood drawn 2 times on Day 1 when they are on dexamethosone. Their parents will complete a sleep diary and fatigue questionnaire by telephone on Days 2 and 5 of both study periods.

Eligibility criteria: Children and adolescents with Leukemia, both genders

Primary outcomes:
measure: Fatigue and sleep quality changes
timeFrame: 10 days
Secondary outcomes:
measure: Pharmacogenetics with dextamethasone use
timeFrame: 5 days
measure: Pharmacokinetics with dextamethasone use
timeFrame: 5 days
Other outcomes:
Locations:
city: Memphis
country: United States
facility: St. Jude Children Research Hospital
state: Tennessee
Study officials:
affiliation: St. Jude Children's Research Hospital
name: Pamela S Hinds, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00259701: Microvascular Reactivity.
Official title: Transdermal Application of Acetylcholine and Nitroglycerin Without Iontophoresis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Retinopathy
Vascular Pathology
Keywords: endothelium
iontophoresis
acetylcholine
nitroglycerin
vasodilation
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2005-11-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: This study attempts to test capillary responses to various challenges without the need for iontophoresis (electrical current).

Detailed description: Studies of microvascular responsiveness often employ iontophoresis to fascilitate drug absorption. Iontophoresis is a confounding stimulus in such studies, and we are attempting to create tests of the microvasculature that do not require iontophoretic drug delivery.

Eligibility criteria: Inclusion Criteria: diabetic. -

Exclusion Criteria: not on nitrates or mydriatic eye drops within 48 hours.

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New HAven
country: United States
facility: Yale School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: David G Silverman
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schonberger RB, Worden WS, Shahmohammadi K, Menn K, Silverman TJ, Stout RG, Shelley KH, Silverman DG. Topical non-iontophoretic application of acetylcholine and nitroglycerin via a translucent patch: a new means for assessing microvascular reactivity. Yale J Biol Med. 2006 Mar;79(1):1-7.
Clinical trial NCT01681901: Ultrasound in Detecting Lymph Node Metastasis in Older Patients Undergoing Breast Sonography
Official title: Lymph Node Evaluation in the Axilla of Symptomatic Older Women During Breast Sonography.
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Breast Cancer
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2012-09-10
Enrollment: 0
Sex: FEMALE
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inclusion Criteria:

* Patients referred for a breast ultrasound
* Patients who have had a mammogram with a Breast Imaging Reporting and Data System (BIRADS) of \>= 4
* Patients who are undiagnosed for breast cancer

Brief summary: This pilot clinical trial studies ultrasound in detecting lymph node metastasis in older patients with undergoing breast sonography. Diagnostic procedures, such as ultrasound, may help find breast cancer and find out how far the disease has spread

Detailed description: PRIMARY OBJECTIVES:

I. To develop a reliable and consistent set of guidelines for utilizing diagnostic ultrasound to assess axillary lymph nodes for patient suspicious of breast cancer with possible nodal metastasis.

SECONDARY OBJECTIVES:

I. To explore whether the data collected can be used for pathologic validation of metastatic disease.

OUTLINE:

Patients undergo breast ultrasound.

Eligibility criteria: Inclusion Criteria:

* Patients referred for a breast ultrasound
* Patients who have had a mammogram with a Breast Imaging Reporting and Data System (BIRADS) of \>= 4
* Patients who are undiagnosed for breast cancer

Exclusion Criteria:

* Patients who have had breast cancer surgery

Primary outcomes:
measure: Proportion of successful evaluations, defined as the consistent capture of the data for geometry, morphology, qualitative vascular information, and quantitative vascular information on 3 axillary lymph nodes
timeFrame: at 15 minutes following breast sonogram
Secondary outcomes:
measure: Accuracy of lymph node geometry, measured with a longitudinal and transverse ratio, to determine guidelines for characterizing micro metastases to the lymph nodes
timeFrame: 3 months
measure: Accuracy of lymph node morphology, assessed for shape and echogenicity, to determine guidelines for characterizing micro metastases to the lymph nodes
timeFrame: 3 months
measure: Accuracy of lymph node vascularity, assessed with color doppler, to determine guidelines for characterizing micro metastases to the lymph nodes
timeFrame: 3 months
measure: Accuracy of lymphatic flow, measured with spectral doppler, to determine guidelines for characterizing micro metastases to the lymph nodes
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Ohio State University Comprehensive Cancer Center
name: Kevin Evans
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05701501: Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD
Official title: Clinical Study of Vitamin B5 in Adjuvant Treatment of Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inflammatory Bowel Diseases
Keywords: Vitamin B5,treatment
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
Collaborators: name: The University of Science and Technology of China
First posted: 2023-01-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with IBD are randomized to oral administration of vitamin B5 and placebo based on the standard treatment, exploring whether Vitamin B5 can increase the clinical remission rate of IBD patients and improve the treatment effect.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with IBD according to the consensus on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018, DOI:10.19538/j.nk2018090106);
* Have complete medical history data;
* Volunteer to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

* Hemophilic patients;
* There are abdominal abscesses, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy;
* Other autoimmune diseases, hematological diseases, tumors, acute infection, severe liver and kidney insufficiency, serious diseases such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis B, liver cirrhosis, kidney disease and mental diseases;
* Take calcium pantothenate preparation in recent 3 months;
* Have a history of abuse of psychoactive substances;
* Pregnant or lactating women, or plan to be pregnant in the next 6 months;
* Nervous system diseases: such as Alzheimer's disease, stroke, Parkinson's disease;
* Participate in other clinical trials in the past 6 months;
* Incomplete medical record information (including gender, age, diagnosis information, colonoscopy results, pathological diagnosis results and other demographic data)

Primary outcomes:
measure: Clinical remission rate
timeFrame: Through study completion, an average of 12 months.
Secondary outcomes:
measure: Disease activity score of IBD patients
timeFrame: Through study completion, an average of 12 months.
measure: Histological remission
timeFrame: Through study completion, an average of 12 months.
measure: Clinical response
timeFrame: Through study completion, an average of 12 months.
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital
Study officials:
affiliation: Changhai Hospital
name: Zhaoshen Li, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Science and Technology of China
name: Shu Zhu, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00736801: Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
Official title: Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Allergic Asthma
Keywords: Airway hyperresponsiveness
Lead sponsor: University of Rostock
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2008-08-18
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years, a physician's diagnosis of allergic asthma
* A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite)
* A pre-bronchodilator forced expiratory volume in the first second (FEV1) \> 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of \< 8 mg histamine / ml

Exclusion Criteria:

* No regular treatment (only short-acting inhalers on demand were allowed)
* No history of or evidence for any other chronic disease than asthma
* No history of smoking, absence of any signs or symptoms of an infection

Primary outcomes:
measure: BDNF concentrations in serum, platelets and plasma
timeFrame: 2006 - 2007
Secondary outcomes:
measure: Airway hyperresponsiveness
timeFrame: 2006 - 2007
Other outcomes:
Locations:
city: Rostock
country: Germany
facility: University of Rostock
Study officials:
affiliation: University of Rostock
name: Johann C. Virchow, MD, FCCP
role: STUDY_CHAIR
References:
citation: Lommatzsch M, Schloetcke K, Klotz J, Schuhbaeck K, Zingler D, Zingler C, Schulte-Herbruggen O, Gill H, Schuff-Werner P, Virchow JC. Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med. 2005 Jan 15;171(2):115-20. doi: 10.1164/rccm.200406-758OC. Epub 2004 Oct 29.
citation: Lommatzsch M, Lindner Y, Edner A, Bratke K, Kuepper M, Virchow JC. Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax. 2009 Sep;64(9):763-9. doi: 10.1136/thx.2008.110916. Epub 2009 Feb 22.
Clinical trial NCT00401401: Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Official title: An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Head and Neck Cancer
Squamous Cell Cancer
Lead sponsor: Genmab
Sponsor class: INDUSTRY
First posted: 2006-11-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer


Eligibility criteria: Inclusion Criteria:

* Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx

Exclusion Criteria:

* Prior treatment with radiotherapy in the head and neck area
* Prior treatment with chemotherapy
* Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors)
* Previous surgery with curative intent for head and neck cancer

Primary outcomes:
measure: Adverse Events
timeFrame: Overall Study
Secondary outcomes:
measure: Overall Response
timeFrame: Up to 3 years
measure: Time to Response
timeFrame: Up to 3 years
measure: Best Overall Tumor Response
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health Sciences Center
state: Oregon
city: Brussels
country: Belgium
facility: St-Luc University Hospital
city: Leuven
country: Belgium
facility: University Hospital Gasthuisberg
city: Dijon
country: France
facility: Centre Georges-Francois Leclerc Hospital
city: Tours
country: France
facility: Hopital Bretonneau Clinique d'Oncologie et Radiothérapie
city: Nijmegen
country: Netherlands
facility: Nijmegen University Hospital
city: Lund
country: Sweden
facility: Lund University Hospital
Study officials:
affiliation: St-Luc University Hospital, Brussels, Belgium
name: Vincent Gregoire, MD professor
role: PRINCIPAL_INVESTIGATOR
References: